FOURIER Results in Detail: Numbers, Subgroups, and Time Course

At a glance

Detail	Value
N	27,564
Intervention	Evolocumab 140 mg Q2W or 420 mg monthly (patient choice)
Comparator	Matching placebo + background statin
Median follow-up	2.2 years (range up to 3.25 years)
Primary endpoint	Composite of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization
Key result	HR 0.85 (95% CI 0.79-0.92; p <0.001)

Trial Design and What the Abstract Leaves Out

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled patients aged 40-85 with clinically evident atherosclerotic cardiovascular disease and an LDL-C of 70 mg/dL or higher (or non-HDL-C of 100 mg/dL or higher) despite optimized statin therapy. Enrollment ran from February 2013 to June 2015 across 1,242 sites in 49 countries. The primary publication in NEJM described a randomized, double-blind, placebo-controlled event-driven design requiring 1,630 primary endpoint events.

Several design choices matter for interpreting the results. Patients could select either the biweekly 140 mg subcutaneous injection or the monthly 420 mg dose, and they could switch between these during the trial. Roughly 75% of patients in the evolocumab arm used the monthly dosing schedule. Both regimens produced equivalent LDL-C lowering, which simplified interpretation but created a pragmatic hybrid dosing population unlike most other cardiovascular outcome trials.

The background statin intensity was high: 69.3% of participants were on high-intensity statins, and the median baseline LDL-C was 92 mg/dL. This positioned FOURIER as a test of "how low can you go" rather than a test of LDL-lowering from a high baseline.

Primary Endpoint: Dissecting the 15% Reduction

The primary composite endpoint occurred in 1,344 of 13,784 patients (9.8%) in the evolocumab group versus 1,563 of 13,780 (11.3%) in the placebo group. That absolute risk reduction of 1.5 percentage points over 2.2 years translates to a number needed to treat (NNT) of approximately 67 over the median follow-up period.

HealthRX.com FOURIER Endpoint Decomposition Framework

Breaking the primary composite into its individual components reveals where the benefit concentrated:

The signal was driven almost entirely by reductions in MI, stroke, and revascularization. Cardiovascular death showed no benefit whatsoever (HR 1.05). This is the single most debated aspect of the FOURIER results. The primary FOURIER publication reported all-cause mortality numerically higher in the evolocumab arm (444 vs. 426 deaths), though this was not statistically significant.

The Key Secondary Endpoint Told a Cleaner Story

The prespecified key secondary endpoint, a harder composite of CV death, MI, or stroke (excluding the softer components of unstable angina hospitalization and revascularization), showed a 20% relative risk reduction: HR 0.80, 95% CI 0.73-0.88, p <0.001. This endpoint is more clinically meaningful because it strips out revascularization, which can be influenced by physician awareness of LDL levels despite blinding.

In absolute terms, this harder endpoint occurred in 5.9% of evolocumab patients versus 7.4% of placebo patients, an absolute reduction of 1.5 percentage points and an NNT of approximately 67 over 2.2 years.

Time-Course Pattern: The Benefit Was Not Immediate

One of the most clinically relevant observations from FOURIER was the time-dependent accrual of benefit. The Kaplan-Meier curves for the primary endpoint did not clearly separate until approximately 6 months after randomization. For the key secondary endpoint, the divergence became more pronounced over time:

In the first year, the primary endpoint HR was approximately 0.90. Beyond 12 months, it dropped closer to 0.80. This time-dependent pattern has important clinical implications: patients who discontinued evolocumab early would not capture the full benefit, and the relatively short median follow-up of 2.2 years likely underestimates the long-term absolute risk reduction. The open-label extension study (FOURIER-OLE) later confirmed that benefits continued to accrue over 5 additional years of follow-up, with a signal toward reduced cardiovascular mortality that the parent trial lacked the duration to detect.

LDL-C Reduction: The Distribution Matters

At 48 weeks, the median LDL-C in the evolocumab arm was 30 mg/dL, down from a baseline median of 92 mg/dL. That represents a 59% reduction from baseline. The placebo arm held steady at a median of 90 mg/dL.

The 25th to 75th percentile range in the evolocumab group was approximately 19-46 mg/dL. Roughly 42% of patients achieved an LDL-C below 25 mg/dL. A prespecified analysis found that the relationship between achieved LDL-C and cardiovascular events was log-linear down to LDL levels around 20 mg/dL, with no apparent lower threshold where benefit plateaued. This finding influenced the 2018 AHA/ACC Cholesterol Guidelines, which endorsed PCSK9 inhibitors for patients with ASCVD not reaching LDL goals on maximally tolerated statin therapy.

Subgroup Analyses: Who Benefited Most?

Prespecified subgroup analyses showed consistent benefit across most categories. There were no significant interactions by age, sex, baseline LDL-C level, statin intensity, diabetes status, or qualifying atherosclerotic disease type. Several subgroups warrant specific attention:

Baseline LDL-C: Patients with baseline LDL-C above the median (92 mg/dL) showed a numerically larger absolute risk reduction, but the relative risk reduction was similar across baseline LDL quartiles. This is consistent with the principle that absolute benefit scales with baseline risk and LDL burden.

Diabetes: Approximately 37% of participants had diabetes at baseline. The diabetes subgroup analysis found consistent relative risk reductions regardless of diabetes status, though patients with diabetes had higher absolute event rates and therefore greater absolute benefit.

PAD subgroup: Patients with peripheral artery disease (13% of enrollment) represented a particularly high-risk subset. A dedicated PAD analysis showed that evolocumab reduced major adverse limb events by 42% (HR 0.58, 95% CI 0.38-0.88) in addition to the MACE benefit, making this one of the strongest signals in any subgroup.

Polyvascular disease: Patients with atherosclerotic disease in multiple vascular beds had both higher absolute event rates and consistent relative benefit, amplifying the absolute risk reduction.

Safety and the Neurocognitive Question

The overall serious adverse event rate was similar between groups. The most common drug-related complaint was injection-site reactions (2.1% evolocumab vs. 1.6% placebo). There was no excess of new-onset diabetes, liver enzyme elevations, or myalgia beyond what was seen with placebo.

Neurocognitive function received special scrutiny because of early concerns about very low LDL-C levels and brain cholesterol homeostasis. The FOURIER parent trial found no difference in neurocognitive adverse events. A dedicated substudy, EBBINGHAUS, prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery in 1,974 patients and found no difference between evolocumab and placebo over a median of 19 months, even among patients achieving LDL-C <25 mg/dL. The Repatha prescribing information reflects these findings.

Binding Anti-Drug Antibodies

Binding antibodies to evolocumab developed in 0.3% of patients in the evolocumab group. No neutralizing antibodies were detected. This is a reassuring finding for a monoclonal antibody administered over years, as immunogenicity can erode efficacy over time.

Limitations the Authors Acknowledged

The FOURIER investigators were transparent about several limitations in the primary publication:

1. Short follow-up: The median 2.2 years was driven by event accrual rather than fixed duration. Given the time-dependent benefit pattern, this almost certainly underestimated the mature treatment effect.

2. No CV death reduction: The trial was not powered to detect a difference in cardiovascular mortality as an individual endpoint. The time-course data suggested a potential late separation, but 2.2 years was insufficient.

3. Stable ASCVD only: FOURIER excluded acute coronary syndrome patients. The companion ODYSSEY OUTCOMES trial with alirocumab addressed that population.

4. Enriched population: All patients had established ASCVD. The results cannot be directly extrapolated to primary prevention populations.

5. Adjudication of soft endpoints: Coronary revascularization and hospitalization for unstable angina are influenced by clinical judgment. The harder secondary endpoint (CV death, MI, stroke) is more objective.

Clinical Translation

FOURIER established the proof of concept that PCSK9 inhibition reduces MACE in statin-treated patients with established ASCVD. The FDA expanded the Repatha label in December 2017 to include cardiovascular risk reduction based on these results.

The practical question for clinicians is identifying which patients justify the cost. The 2018 ACC/AHA guidelines recommend PCSK9 inhibitors for patients with ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. Since FOURIER's publication, the list price of evolocumab has dropped from approximately $14,000/year to roughly $5,850/year, substantially improving cost-effectiveness ratios from the initial unfavorable estimates.

The PAD subgroup, patients with polyvascular disease, and those with recurrent events on maximally tolerated therapy represent the patients with the highest absolute benefit and the strongest clinical rationale for PCSK9 inhibitor therapy based on FOURIER data.

Frequently asked questions

›What was the primary endpoint result in FOURIER?

The primary composite of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization occurred in 9.8% of evolocumab patients versus 11.3% of placebo patients. HR 0.85 (95% CI 0.79-0.92, p <0.001), a 15% relative risk reduction over a median 2.2 years.

›Did evolocumab reduce cardiovascular death in FOURIER?

No. Cardiovascular death showed no reduction (HR 1.05, 95% CI 0.88-1.25). The benefit was driven by reductions in MI, stroke, and coronary revascularization. The open-label extension study later suggested a potential late mortality benefit with longer follow-up.

›How low did LDL cholesterol go in the evolocumab group?

Median LDL-C reached 30 mg/dL at 48 weeks (down from 92 mg/dL at baseline), a 59% reduction. About 42% of patients achieved LDL-C below 25 mg/dL. Benefit appeared to continue down to LDL levels around 20 mg/dL with no lower threshold detected.

›How long did it take for the benefit to appear?

Kaplan-Meier curves did not clearly separate until approximately 6 months. The treatment effect strengthened over time, with the HR closer to 0.80 beyond 12 months compared to approximately 0.90 in the first year.

›Were there safety concerns with very low LDL-C levels?

No significant safety signals emerged. The EBBINGHAUS neurocognitive substudy found no cognitive decline even at LDL-C levels below 25 mg/dL. Injection-site reactions were the most common drug-related adverse event at 2.1%.

›Which patients benefited most from evolocumab in FOURIER?

Relative risk reductions were consistent across most subgroups. Patients with peripheral artery disease saw a 42% reduction in major adverse limb events. Those with polyvascular disease and higher baseline LDL-C had the greatest absolute risk reductions.

›What is the number needed to treat for evolocumab based on FOURIER?

Approximately 67 patients treated for 2.2 years to prevent one primary endpoint event. This NNT improves with longer treatment duration given the time-dependent benefit pattern shown in the trial and its extension study.

›How does FOURIER compare to the ODYSSEY OUTCOMES trial with alirocumab?

FOURIER enrolled stable ASCVD patients while ODYSSEY OUTCOMES enrolled recent acute coronary syndrome patients. Both showed MACE reductions of similar magnitude (15% and 15%, respectively). ODYSSEY OUTCOMES showed a signal toward reduced all-cause mortality in a prespecified high-risk subgroup, which FOURIER did not.

›Did FOURIER lead to FDA label changes for evolocumab?

Yes. In December 2017, the FDA approved a cardiovascular risk reduction indication for Repatha (evolocumab) based on FOURIER, expanding the label beyond its original LDL-lowering indication.

›What was the statin background therapy in FOURIER patients?

Approximately 69.3% of patients were on high-intensity statin therapy. The median baseline LDL-C of 92 mg/dL despite optimized statin use reflects the residual LDL burden that evolocumab targeted.

References

• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed
• O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease (FOURIER-OLE). Circulation. 2022;146(15):1109-1119. PubMed
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. PubMed
• Repatha (evolocumab) Prescribing Information. Amgen Inc. FDA Label
• Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 2018;137(4):338-350. PubMed
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular Safety and Efficacy of the PCSK9 Inhibitor Evolocumab in Patients With and Without Diabetes. Lancet Diabetes Endocrinol. 2017;5(12):941-950. PubMed